Stem cells promise to revolutionn traditional heart surgery!

British researchers have found that interstity stem cells (MSCs) can replace transplants that used to require repeated implants and can be used for restorative surgery.
stem cells can be implanted once to fully integrate into the heart tissue and grow with them.
can reduce the number of operations newborns need because they have certain congenital heart conditions.
recent years, interstititional stem cells in the field of heart disease research has made breakthroughs, but also people gradually realized that stem cells are expected to bring about changes in traditional heart surgery.
disease: the number one killer of health cardiovascular disease is currently leading to the death of urban and rural residents in China's number one killer.
, according to the China Cardiovascular Report 2016, there are 290 million cardiovascular patients in China.
the cardiovascular system refers to the blood circulation system, including the heart and blood vessels.
Cardiovascular disease includes a variety of related diseases, is a very large clinical concept, including: isohythmic heart disease (coronary heart disease / myocardial infarction), perivascular artery disease, arrhythmic disorder, hypertension, heart failure, heart valve disease, cardiomyopathy, aortic disease and pulmonary embolism.
heart disease and congestive heart failure continue to be the leading causes of high morbidity and mortality from cardiovascular disease.
loss of myocardial cells after myocardial infarction causes cardiac contraction dysfunction, and dead myocardial cells are replaced by fibroblasts, forming scar tissue.
stem cell-based treatment is designed to regenerate damaged heart muscle, an emerging treatment model.
20 years ago, Lazarus conducted the first applied study of interstitiotic stem cell injections in patients with malignant blood disorders.
Since then, a large number of clinical trials have tested the feasibility and effectiveness of interstitial stem cell therapy, involving diseases such as graft anti-host disease, blood malignancies, organ transplantation, cardiovascular disease, neurological disease, autoimmune diseases, and organ transplantation.
1,212 clinical trials based on mesochargic stem cells had been completed or were still in progress as of December 2020, according to data reported by the National Institutes of Health (clinicaltrial.gov).
1: In clinical trials based on mesochargic stem cells, a large proportion (14.8%) of research on cardiovascular disease (Figure 1) shows very good prospects for treatment.
a wealth of evidence from preclinical animal studies and clinical trials suggests that interstitial or mixed bone marrow stem cell groups injected into coronary arteries may be a simple and effective treatment for heart disease.
Notes: The table content is compiled from Stem Cell Translational Medicine, and the specific project information can be used to query the clinical treatment of acute myocardial infarction on the website of clinicaltrials.gov, and 69 patients were recruited to undergo emergency angiosis or angioplasty within 12 hours of a heart attack.
interventional treatment of the coronary artery, the patients were randomly divided into the coronary artery injection bone marrow interstumin stem cell group (34 cases) and the physiological saline group (35 cases).
3 months, cell movement in the heart infarction area of the MSC treatment group increased significantly compared to the control group, and heart function improved.
2011, researchers evaluated for the first time the safety and effectiveness of intraostopically recharged stem cells injected into the heart in patients with stable coronary artery disease and resoicable angina.
the results of this study were quite encouraging, with significant improvements in left achroom function and motor skills in patients treated with interstate stem cells, as well as improvements in clinical symptoms and angina questionnaire assessment.
, these results were confirmed again.
a Phase II trial conducted in another laboratory, in which a total of 60 patients with chronic ishemic heart failure were randomly injected with intermyocardial stem cells or placebos at a 2:1 scale.
12 months, injected interstumined stem cell infusions appeared to induce the regeneration of damaged myocardial tissue, confirming the safety of treatment and improved function of the damaged heart.
foreign scholars also conducted a noteworthy Phase I/II clinical trial in which patients with isotopic cardiomyopathy were treated with intramyal injections of heterogenous and self-contained prosthetic stem cells.
results showed that both isomer and autobiographical cells were safe, and both cells showed potential regenerative biological activity in patients with ischemic cardiomyopathy, which reduced infarction area and improved cercardial reconstruction.
clinical transformation advantages of interstitiocharged stem cells have been highlighted so far, a considerable number of studies have proved the therapeutic effect of interstit rate stem cell transplantation, although the exact potential mechanism is still unclear.
these potential effects are thought to come from the side secretion effects of bioactive molecules released by interstumined stem cells, which in turn activate the resident cells in the heart to grow new blood vessels and myocardial cells.
completed and ongoing clinical trials have confirmed the safety of interstitition stem cell therapy and demonstrated good tolerance for interstity stem cell infusion.
preclinical evidence suggests that infusion of infusions of pre-differentiated interstitial charged stem cells can promote the recovery of heart tissue after injury.
, unlike undifferentiated interstitial charge stem cells, pre-differentiated interstitial stem cells have immune advantages and survive in the heterogeneous heart muscle for a long time, leading to significant improvements in heart function.
the future, there is still a lot of work to be done to transform from clinical to widespread use.
such as heterogeneity of the body, insotroplification, immunogenicity and cryogenic preservation, these need to be considered.
clinical application of interstate charge stem cells should also be standardized development, so that the application of interstumogenic stem cell tissue damage or immune diseases and other diseases to get better treatment.
Knot as CCTV-2 "First Time" column, reporters in the direct hit G20 special report said: If there is a heart problem, you can do the operation directly on the heart cell patch, so as to complete the heart repair work.
this technology will be realized in the near future.
stem cell-based "heart regeneration therapy" and "heart patches" are increasingly in the public eye, and such technologies are expected to become new options for heart surgery in the future.
references: 1.Wang, J. ; Liao, L. ; Tan, J.Mesenchymal-stem-cell-based experimental and clinical trials: Current status and open questions. Expert Opin. Biol. Ther. 11(7):893–909; 2011. Alfarano, C. ; Roubeix, C. ; Chaaya, R. ; Ceccaldi, C. ; Calise, D. ; Mias, C. ; Cussac, D. ; Bascands, J. L. ; Parini, A.Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant. 21(9):2009–2019; 2007. Delcarpio, J.B. Claycomb, W.C.Cardiomyocyte transfer into the country heart. Cell-to-cell interactions in vivo and in vitro. Ann. NY Acad. Sci. 752:267–285; 1995. Tomita, S. ; Li, R. K. ; Weisel, R. D. ; Mickle, D. A. ; Kim, E. J. ; Sakai, T. ; Jia, Z. Q.Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100(19 Suppl):II247–256; 1999. Giordano, A. ; Galderisi, U. ; Marino, I. R.From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J. Cell Physiol. 211(1):27–35; 2007. Martin, J. ; Helm, K. ; Ruegg, P. ; Varella-Garcia, M. ; Burnham, E. ; Majka, S.Adult lung side population cells have mesenchymal stem cell potential. Cytotherapy 10(2):140–151; 2008. Katritsis, D. G. ; Sotiropoulou, P. A. ; Karvouni, E. ; Karabinos, I. ; Korovesis, S. ; Perez, S. A. ; Voridis, E.M. ; Papamichail, M.Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter. Cardiovasc. Interv. 65(3):321–329; 2005. Friis, T. ; Haack-Sorensen, M. ; Mathiasen, A.B. Ripa, R. S. ; Kristoffersen, U. S. ; Jorgensen, E. ; Hansen, L. ; Bindslev, L. ; Kjaer, A. ; Hesse, B. ; Dickmeiss, E. ; Kastrup, J.Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand. Cardiovasc. J. 45(3):161–168; 2011. Mathiasen, .B. Jorgensen, E. ; Qayyum, A. A. ; Haack-Sorensen, M. ; Ekblond, A. ; Kastrup, J.Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived mesenchymal stromal cells in chronic ischemic heart failure (MSC-HF Trial). Am. Heart J. 164(3):285–291; 2009.